Prevention & lipidsResearch article
Reappraisal of statin primary prevention trials: implications for identification of the statin-eligible primary prevention patient
- Critical reappraisal of primary prevention statin randomized clinical trials (RCTs)
Authors' conclusion
Results of primary prevention RCTs justify treatment of more subjects and lower risk subjects than current risk algorithm-based guidelines.
Study context
- Population
- Enrollees of RCTs cited in North American and European dyslipidaemia guidelines justifying primary prevention statins
- Comparison
- Statin eligibility by minimal RCT enrolment criteria vs by risk algorithms (Framingham, pooled cohort equation, SCORE2)
Main finding
As reported in the abstract
Statin eligibility of patients meeting minimal RCT enrolment criteria by risk algorithms (Framingham, pooled cohort equation, SCORE2); enrollee characteristics · 10 year risk
Enrollee age
63.9 ± 8.9 years (mean ± SD)
Enrollee low density lipoprotein-cholesterol (LDL-C)
3.53 ± 0.91 mmol/L
Original publication
Reappraisal of statin primary prevention trials: implications for identification of the statin-eligible primary prevention patient. Eur J Prev Cardiol. Published 25 February 2025. doi:10.1093/eurjpc/zwaf048
Summarised from the published abstract; every number is checked against it